Abstract: Various embodiments of child-resistant containers are described which have a release that requires two portions to be simultaneously depressed in order to release the latches and allow the container to be opened. The release may be formed of two pieces coupled to each other and the housing by a fastener, where one of the pieces acts as a spring to bias the release or its actuators in a first position.

Abstract: Various embodiments of child-resistant containers are described which have a release that requires two portions to be simultaneously depressed in order to release the latches and allow the container to be opened. The release may be formed of two pieces coupled to each other and the housing by a fastener, where one of the pieces acts as a spring to bias the release or its actuators in a first position.

Abstract: Various embodiments of child-resistant containers are described which have a release that requires two portions to be simultaneously depressed in order to release the latches and allow the container to be opened. The release may be formed of two pieces coupled to each other and the housing by a fastener, where one of the pieces acts as a spring to bias the release or its actuators in a first position.

Abstract: This disclosure provides agents, compositions and methods of treating cancer by inhibiting histone lysine specific demethylase 1 (LSD1) and/or and a histone lysine specific demethylase 2 (LSD2). Agents and compositions comprise statins and/or inhibitors of LSD1/2.

Abstract: This disclosure provides agents, compositions and methods of treating cancer by inhibiting histone lysine specific demethylase 1 (LSD1) and/or and a histone lysine specific demethylase 2 (LSD2). Agents and compositions comprise statins and/or inhibitors of LSD1/2.

Abstract: Disclosed herein are methods of detecting malignancy in a tumor of a subject comprising measuring the amount of 5-hmC in a tumor sample and comparing to a control to thereby detect a level of reduction of 5-hmC in the tumor, wherein the tumor is characterized as malignant if a threshold level of reduction is detected. The tumor may be a solid tumor such as a melanocytic lesion. Also disclosed are methods of determining the prognosis of a subject with a tumor by determination of the amount of 5-hmC in the tumor. Methods for treatment of a tumor with reduced 5-hmC are also disclosed.

Abstract: This disclosure provides agents, compositions and methods of treating cancer by inhibiting histone lysine specific demethylase 1 (LSD1) and/or and a histone lysine specific demethylase 2 (LSD2). Agents and compositions comprise statins and/or inhibitors of LSD1/2.